A Tale of Two Companies: SG&A Expenses of Pfizer Inc. and Vericel Corporation

In the world of pharmaceuticals, operational efficiency is key to success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Pfizer Inc. and Vericel Corporation, from 2014 to 2023.

Pfizer Inc.: A Giant's Steady Course

Pfizer, a global leader, consistently maintained high SG&A expenses, averaging around $14 billion annually. Despite a dip in 2020, likely due to pandemic-related adjustments, Pfizer's expenses rebounded by 2023, reflecting a 27% increase from the 2020 low.

Vericel Corporation: A Rising Star

In contrast, Vericel, a smaller entity, showcased a remarkable growth trajectory. Starting with modest expenses in 2014, Vericel's SG&A costs surged by over 800% by 2023, indicating aggressive expansion and investment in operational capabilities.

This comparison highlights the diverse strategies of established giants and emerging innovators in the pharmaceutical sector.